IMO Health releases value sets to support COVID-19 vaccinations

For much of 2020, the world waited with bated breath for the development of a COVID-19 vaccine. Now, with two vaccines approved for use by the FDA, attention is turning to rollout. Today, IMO Health is proud to announce the release of new value sets within our IMO Precision Sets suite that will help track and coordinate coronavirus vaccinations.
Published
COVID-19
Written by
Picture of Alice Kiehl
Senior Product Marketing Manager

IMO Health is pleased to announce that effective today, January 8, 2021, our IMO Precision COVID-19 Sets will be expanded to include new value sets that help with prioritization needs related to COVID-19 vaccination, as well as long-term risks stemming from the novel coronavirus.

This offering, which will be available within our IMO Precision Sets web portal, will be released to customers free of charge. Our coronavirus-specific value set solution – part of the larger IMO Precision Sets offering – was initially released in March 2020, with the goal of helping providers handle workflow issues and manage patient cohorts connected to the new coronavirus. With two vaccines currently approved by the FDA and being administered throughout the country, IMO Health’s team remains committed to ensuring providers have the tools required to easily identify, monitor, and track their COVID-19 patient population – including vaccination history.

Importantly, the IMO Precision COVID-19 Sets suite now includes a Comorbid Risk category. Comprised of 26 individual value sets, this update allows providers to easily determine which patients may be at higher risk for complications from COVID-19, and who should therefore be prioritized to receive the vaccine. Additionally, a new value set offering within the suite is designed specifically to identify patients who experience adverse reactions to the vaccine. Finally, the IMO Precision COVID-19 Sets now includes a value set specifically for identifying patients with post-COVID-19 complications.

Related Content

Blog digest signup

Resources sent straight to your inbox.

Latest Resources​

Better cohorts mean better evidence. Discover how to cut through messy data with clinically intelligent terminology.
Life sciences data is expensive – make sure it’s worth it. Learn how to maximize RWD investments and boost ROI through smarter...
At ISPOR 2025, experts explored how GenAI is helping close evidence gaps in rare diseases – turning messy data into reliable, reproducible...